Publications

Publications

Filter Results: (3) Arrow Down

Show Results For

Mark BaumRemove Mark Baum →

Page 1 of 3 Results
Faculty

Mark L. Egan

Mark Egan is the Mark Kingdon Associate Professor of Business Administration in the Finance Unit, teaching Corporate Financial Operations to MBA students. Professor Egan’s research concentrates on the intersection of corporate finance and industrial organization. His current research agenda explores how consumers access financial markets through banks and brokerage firms. His work has been cited...
Faculty

Mark N. Roberge

Mark Roberge is a Senior Lecturer in the Entrepreneurial Management Unit at the Harvard Business School.  He teaches Entrepreneurial Sales and Marketing in the second-year MBA program in the Fall term and The Entrepreneurial Manager and Startup Bootcamp in the first-year MBA program in the Spring and Winter terms.  Prior to HBS, Mark served as SVP of Global Sales and Services at HubSpot (NYSE:...

Are you looking for?

→Search All HBS Web
  • April 2017
  • Case

Imprimis (A)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case examines the strategic choices and evolving business model of Imprimis Pharmaceuticals from the perspective of CEO Mark Baum. The (A) case provides a brief history of the company and of the compounding business, outlining the challenges faced by Imprimis in... View Details
Keywords: Strategy; Healthcare; Drug Compounding; Pharmaceuticals; Compounding; Drug Development; Decision-making; Mark Baum; Imprimis; Small Business; Decisions; Cost vs Benefits; Business Strategy; Business Model; Decision Choices and Conditions; Pharmaceutical Industry; United States
Related
  • April 2017
  • Supplement

Imprimis (B)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A). It describes the company’s decision to enter into the pharmaceutical compounding business in 2013–2014. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients’... View Details
Keywords: Healthcare; Drug Compounding; Drug Development; Pharmaceuticals; Small Business; Decision-making, Business Model; Mark Baum; Imprimis; Decision Making; Strategy; Health Care and Treatment; Policy; Pharmaceutical Industry; United States
Related
  • April 2017
  • Supplement

Imprimis (C)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A & B). Set in 2015, it first describes Imprimis’s decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the... View Details
Keywords: Health Care and Treatment; Cost; Moral Sensibility; Competitive Strategy; Decision Choices and Conditions; Pharmaceutical Industry; United States
Related